Besides the in-house activities of research and development, always resulting in the manufacturing of new medicinal products, Italfarmaco considers the in-licensing activities of new products and technologies as the key factor for its growth.
除了总是导致新医药产品生产的内部研发活动外，Italfarmaco 还认为新产品和技术的内部许可活动是其增长的关键因素。

In addition, with the goal of expanding the presence of products developed in-house in the various territories not covered by its subsidiaries, Italfarmaco establishes business agreements with local partners selected from the best pharmaceutical companies of each Country (Licensing-out).
此外，为了扩大内部开发的产品在其子公司未覆盖的各个地区的存在，Italfarmaco 与从每个国家最好的制药公司中选出的当地合作伙伴建立了业务协议（许可出去）。

Our Licensing Direction– for both in- and out-licensing activities– operates with the goal of creating long-lasting relationships of mutual benefit with all of its licensors and licensees.
我们的许可方向（针对内部和外部许可活动）的运作目标是与所有许可方和被许可方建立持久的互利关系。

In-licensing activities: 引进许可活动：

Italfarmaco is always ready to assess new business opportunities in order to include ground-breaking drugs among the products to be promoted, both to specialists and general practitioners, through its network of scientific information. The process of assessing new opportunities to be included in the product portfolio is very accurate and involves all the Directions of Italfarmaco dealing with clinical development, registration and promotion aimed at highlighting the therapeutic role of new medicinal products and patient benefit.
Italfarmaco 随时准备评估新的商机，以便通过其科学信息网络将突破性药物纳入向专家和全科医生推广的产品中。评估产品组合中新机会的过程非常准确，涉及 Italfarmaco 处理临床开发、注册和推广的所有方向，旨在强调新医药产品的治疗作用和患者利益。

Italfarmaco also assesses new opportunities, for hospital and pharmaceutical markets, related to new formulations capable of meeting all the new medical requirements and offering an advantage to patients (for example: new liquid or sustained-release formulations, pre-filled syringes).
Italfarmaco 还评估了医院和制药市场的新机会，这些机会与能够满足所有新医疗要求并为患者提供优势的新配方有关（例如：新液体或缓释配方、预填充注射器）。

Italfarmaco is also interested in innovative medical devices or food supplements in specific therapeutic areas (for example the Gynecological area). Italfarmaco also has a remarkable presence in the following therapeutic areas, which are the cornerstone of its activities: Gynecology; Thrombosis & Cardiovascular; Oncology & Supportive Care; Bone Metabolism; Central Nervous System.
Italfarmaco 还对特定治疗领域（例如妇科领域）的创新医疗设备或食品补充剂感兴趣。 Italfarmaco 在以下治疗领域也占有显着地位，这是其业务的基石：妇科；血栓与心血管；肿瘤学和支持治疗；骨代谢；中枢神经系统。

Out-licensing activities:
对外许可活动：

Italfarmaco is interested in the constant expansion, through targeted partnerships with pharmaceutical companies, of the countries in which in-house-developed products are licensed and marketed.
Italfarmaco 有兴趣通过与制药公司有针对性的合作伙伴关系，不断扩大内部开发产品获得许可和销售的国家。
Our out-licensing activities is mainly focused on the search for new licensors or distributors in the territories where Italfarmaco is not directly present through its subsidiaries.
我们的对外许可活动主要集中在 Italfarmaco 未通过其子公司直接开展业务的地区寻找新的许可方或分销商。

Products available for out-licensing are those belonging to the Central Nervous System area (e.g: choline alfoscerate, liquid formulations of Paroxetine, Venlafaxine, Zolpidem, Riluzole), iron-based and iron derivatives products, folic acid-based products, Combinations of calcium + vitamin D3, food supplements for pregnancy and women’s health.
可对外许可的产品属于中枢神经系统领域（例如：甘磷酸胆碱、帕罗西汀、文拉法辛、唑吡坦、利鲁唑的液体制剂）、铁基和铁衍生物产品、叶酸基产品、钙的组合+ 维生素D3，怀孕和女性健康的食品补充剂。